中枢神经系统状态对T细胞急性淋巴细胞白血病具有预后意义:儿童肿瘤协作组报告
该研究分析儿童肿瘤协作组两项3期临床试验(AALL0434和AALL1231)中2164例新诊断T-ALL患者,评估中枢神经系统白血病累及对预后的影响。结果显示CNS-1与CNS-2患者4年无事件生存率相似,而CNS-3患者预后较差;尽管AALL1231强化化疗以取消颅脑放疗,CNS-1和CNS-2结局仍相似。
要点
- CNS-1与CNS-2的4年无事件生存率相似(85.1% vs 83.2%),CNS-3较低(71.8%)。
- CNS-1与CNS-2的4年总生存率相似(90.1% vs 90.5%),CNS-3为82.7%。
- 奈拉滨在AALL0434中对CNS-3患者显示更优的4年无病生存率(93.1%)。
核心结论
- 诊断时CNS-1与CNS-2状态在T-ALL中接受aBFM治疗时结局相似,CNS-2状态不影响预后。
- CNS-3状态患者预后较差,尽管奈拉滨改善了其结局,仍需新方法。
研究设计与样本
- 分析连续3期儿童肿瘤协作组临床试验AALL0434和AALL1231中新诊断T-ALL患者。
- 共纳入2164例患者(AALL0434 1550例;AALL1231 614例)。
- AALL0434中90.8%参与者接受颅脑放疗,AALL1231中88.2%参与者通过强化化疗取消颅脑放疗。
主要发现
- 1564例为CNS-1(72.3%),441例为CNS-2(20.4%),159例为CNS-3(7.3%)。
- 4年无事件生存率:CNS-1为85.1%±1.0%,CNS-2为83.2%±2.0%,CNS-3为71.8%±4.0%(P=0.0004)。
- 4年总生存率:CNS-1为90.1%±0.8%,CNS-2为90.5%±1.5%,CNS-3为82.7%±3.4%(P=0.005)。
- CNS-1和CNS-2的结局相似,与是否接受颅脑放疗、强化皮质激素或新药无关。
- AALL0434中奈拉滨组4年无病生存率为93.1%±5.2%,CNS-3患者均接受颅脑放疗且EFS/OS较差。
关键数值与推荐
- CNS-1:4年EFS 85.1%±1.0%,4年OS 90.1%±0.8%。
- CNS-2:4年EFS 83.2%±2.0%,4年OS 90.5%±1.5%。
- CNS-3:4年EFS 71.8%±4.0%,4年OS 82.7%±3.4%。
- 奈拉滨组4年无病生存率93.1%±5.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To determine the prognostic significance of central nervous system (CNS) leukemic involvement in newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL), outcomes on consecutive, phase 3 Children's Oncology Group clinical trials were examined. AALL0434 and AALL1231 tested efficacy of novel agents within augmented-Berlin-Frankfurt-Münster (aBFM) therapy. In addition to testing study-specific chemotherapy through randomization, the AALL0434 regimen delivered cranial radiation therapy (CRT) to most participants (90.8%), whereas AALL1231 intensified chemotherapy to eliminate CRT in 88.2% of participants. In an analysis of 2164 patients with T-ALL (AALL0434, 1550; AALL1231, 614), 1564 had CNS-1 (72.3%), 441 CNS-2 (20.4%), and 159 CNS-3 (7.3%). The 4-year event-free-survival (EFS) was similar for CNS-1 (85.1% ± 1.0%) and CNS-2 (83.2% ± 2.0%), but lower for CNS-3 (71.8% ± 4.0%; P = .0004). Patients with CNS-1 and CNS-2 had similar 4-year overall survival (OS) (90.1% ± 0.8% and 90.5% ± 1.5%, respectively), with OS for CNS-3 being 82.7% ± 3.4% (P = .005). Despite therapeutic differences, outcomes for CNS-1 and CNS-2 were similar regardless of CRT, intensified corticosteroids, or novel agents. Except for significantly superior outcomes with nelarabine on AALL0434 (4-year disease-free survival, 93.1% ± 5.2%), EFS/OS was inferior with CNS-3 status, all of whom received CRT. Combined analyses of >2000 patients with T-ALL identified that CNS-1 and CNS-2 status at diagnosis had similar outcomes. Unlike B-ALL, CNS-2 status in T-ALL does not impact outcome with aBFM therapy, without additional intrathecal therapy, with or without CRT. Although nelarabine improved outcomes for those with CNS-3 status, novel approaches are needed. These trials were registered at www.clinicaltrials.gov as #NCT00408005 (AALL0434) and #NCT02112916 (AALL1231).
引用
- Gossai NP, Devidas M, Chen Z, et al. Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report. Blood. 2023. PMID: 36603187. doi:10.1182/blood.2022018653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。